IDYAIDEAYA Biosciences, Inc.

HealthcareUSD
$41.59

Price

$41.59+86%1Y
1M+15%1Y+86%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average
7/10
Value46
Quality54
Momentum77
Growth-
Strongest Momentum, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
What they do

We are a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.

In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR

P/E (TTM)-
Market Cap$2.95B
1Y Return+86%
5Y Return+77%

IDEAYA Biosciences, Inc. (IDYA) reported revenue of $8.9M in Q2 2026 (quarter ended June 30, 2026). That came with net loss of $112M. For the full year FY2025, revenue was $219M (+3024% year on year) and net income −$114M.

Raw charts

8 series · TTM

As reported to the SEC, without any scoring.

Biotechnology

Ranks #82 of 145 by Smart Score

Compare peers
BEAM+0.09%
Beam Therapeutics Inc.
ELVN+2.8%
Enliven Therapeutics, Inc.
GPCR+0.19%
Structure Therapeutics Inc.
DYN+1.4%
Dyne Therapeutics, Inc.
QURE+0.51%
uniQure N.V.
ARQT-2.5%
Arcutis Biotherapeutics, Inc.